gradientForSurfBreak.png

Item List

Business Wire
Endeavor BioMedicines Partners with xCures

Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, and xCures, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence, today announced a partnership that gives patients enrolling in Endeavor's clinical trials access to the xCures platform to find the best available treatment options suited to their individual tumor profile. The partnership helps identify patients whose cancers harbor the PTCH1 mutation and may be eligible for Endeavor’s clinical trial. The xCures platform also enables patients to find more suitable treatment options if they are ineligible.

Recent Posts

General News

Carlsmed.png

At HLTH 2022, a New Chapter for AI
...

MedCity News

General News

Carlsmed.png

HCA CEO to Big Tech: You Can’t Disrupt Healthcare Like You’ve Disrupted Other In ...

MedCity News

Wavemaker 360 News

Carlsmed.png

Wavemaker Three-Sixty Health Celebrates Investment Milestone at HLTH 2022: 50 Co ...

Yahoo

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png